Current status of neuroprotection trials for traumatic brain injury: Lessons from animal models and clinical studies

被引:127
作者
Bullock, MR
Lyeth, BG
Muizelaar, IP
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA
[2] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA
关键词
animal models; clinical trials; Glasgow Outcome Scale; neuroprotection; therapy; traumatic brain injury;
D O I
10.1097/00006123-199908000-00001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
LABORATORY STUDIES HAVE identified numerous potential therapeutic interventions that might have clinical application for the treatment of human traumatic brain injury. Many of these therapies have progressed into human clinical trials in severe traumatic brain injury. Numerous trials have been completed, and many others have been prematurely terminated or are currently in various phases of testing. The results of the completed Phase III trials have been generally disappointing, compared with the expectations produced by the successes of these interventions in animal laboratory studies. In this review, we summarize the current status of human traumatic brain injury clinical trials, as well as the animal laboratory studies that led to some of these trials. We summarize criteria for conducting clinical trials in severe traumatic brain injury, with suggestions for future improvements. We also attempt to identify factors that might contribute to the discrepancies between animal and human trials, and we propose recommendations that could help investigators avoid certain pitfalls in future clinical trials in traumatic brain injury.
引用
收藏
页码:207 / 217
页数:11
相关论文
共 82 条
  • [1] Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15
  • [2] ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65
  • [3] THRESHOLDS IN CEREBRAL-ISCHEMIA - THE ISCHEMIC PENUMBRA
    ASTRUP, J
    SIESJO, BK
    SYMON, L
    [J]. STROKE, 1981, 12 (06) : 723 - 725
  • [4] Cerebral hyperglycolysis following severe traumatic brain injury in humans: A positron emission tomography study
    Bergsneider, M
    Hovda, DA
    Shalmon, E
    Kelly, DF
    Vespa, PM
    Martin, NA
    Phelps, ME
    McArthur, DL
    Caron, MJ
    Kraus, JF
    Becker, DP
    [J]. JOURNAL OF NEUROSURGERY, 1997, 86 (02) : 241 - 251
  • [5] ULTRA-EARLY EVALUATION OF REGIONAL CEREBRAL BLOOD-FLOW IN SEVERELY HEAD-INJURED PATIENTS USING XENON-ENHANCED COMPUTERIZED-TOMOGRAPHY
    BOUMA, GJ
    MUIZELAAR, JP
    STRINGER, WA
    CHOI, SC
    FATOUROS, P
    YOUNG, HF
    [J]. JOURNAL OF NEUROSURGERY, 1992, 77 (03) : 360 - 368
  • [6] BRAAKMAN R, 1994, J NEUROSURG, V80, P797
  • [7] RELATIONSHIP BETWEEN CORTICAL EVOKED-POTENTIAL AND LOCAL CORTICAL BLOOD-FLOW FOLLOWING ACUTE MIDDLE CEREBRAL-ARTERY OCCLUSION IN BABOON
    BRANSTON, NM
    SYMON, L
    CROCKARD, HA
    PASZTOR, E
    [J]. EXPERIMENTAL NEUROLOGY, 1974, 45 (02) : 195 - 208
  • [8] Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion
    Broaddus, WC
    Prabhu, SS
    Gillies, GT
    Neal, J
    Conrad, WS
    Chen, ZJ
    Fillmore, H
    Young, HF
    [J]. JOURNAL OF NEUROSURGERY, 1998, 88 (04) : 734 - 742
  • [9] COGNITIVE SEQUELAE OF SEVERE HEAD-INJURY IN RELATION TO THE GLASGOW OUTCOME SCALE
    BROOKS, DN
    HOSIE, J
    BOND, MR
    JENNETT, B
    AUGHTON, M
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1986, 49 (05) : 549 - 553
  • [10] Strategies for neuroprotection with glutamate antagonists - Extrapolating from evidence taken from the first stroke and head injury studies
    Bullock, R
    [J]. NEUROPROTECTIVE AGENTS: CLINICAL AND EXPERIMENTAL ASPECTS, 1995, 765 : 272 - 278